1. Scrip

Pfizer withdraws Macugen for DMO in Europe

 
• By Sukaina Virji

The original victim of Lucentis' (ranibizumab) efficacy, Pfizer's Macugen, has been officially withdrawn from development in diabetic macular oedema, months after Pfizer handed back another DMO project. The move calls into question not only Pfizer's position in the indication, but also the prospects for a range of other compounds in development for DMO (Table 1)

The original victim of Lucentis' (ranibizumab) efficacy, Pfizer's Macugen, has been officially withdrawn from development in diabetic macular oedema, months after Pfizer handed back another DMO project. The move calls into question not only Pfizer's position in the indication, but also the prospects for a range of other compounds in development for DMO (Table 1)

The European Medicines Agency says it has been formally notified by Pfizer that it is withdrawing its application for an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapeutic Category

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.